Ratings Rohto Pharmaceutical Co.,Ltd.

Equities

4527

JP3982400008

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-21 am EDT			5-day change	1st Jan Change
2,805 ^JPY	-2.65%		-11.74%	-1.34%

Apr. 04	Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen	MT
Apr. 04	Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update	DJ

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ROHTO PHARMACEUTICAL CO.,LTD.	-1.34%	4.21B	-
ELI LILLY AND COMPANY	+37.78%	705B	C+
NOVO NORDISK A/S	+32.82%	583B	B
JOHNSON & JOHNSON	-3.51%	364B	C+
MERCK & CO., INC.	+19.94%	332B	B-
ABBVIE INC.	+5.14%	291B	C+
ASTRAZENECA PLC	+16.64%	238B	B+
ROCHE HOLDING AG	-4.13%	210B	A+
NOVARTIS AG	+10.63%	209B	B-
AMGEN INC.	+9.32%	169B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes